Agilent completes the InfinityLab Bio LC portfolio

Agilent Technologies has launched three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release has been described by Agilent as central to its portfolio of complete Bio LC solutions, featuring instruments, columns, and supplies that integrate with Agilent OpenLab and MassHunter software, and CrossLab services to maximise efficiency in biopharma labs.

The three new systems include the 1290 Infinity II Bio LC System with High-Speed Pump, the 1290 Infinity II Bio LC System with Flexible Pump, and the 1260 Infinity II Prime Bio LC System. These systems are based on InfinityLab LC technology and were designed to help future-proof laboratories by providing a platform that is reliable and delivers performance with additional bio-analysis capability and resistance to harsh analytical conditions.

“This is a significant portfolio release that further demonstrates Agilent’s commitment to the fast- growing biopharma LC market” said Stefan Schuette, Vice President and General Manager of Agilent’s Liquid Phase Separations Division. “By offering new instruments, columns, application kits, and supplies we’re providing solutions that customers can tailor to meet their specific bio-analytical requirements, including seamless transfer of existing methods from both Agilent and non-Agilent LC systems.”

Agilent has also announced the planned release of several new workflow solutions based on the Bio LC core systems. These specialised solutions include a new, biocompatible 2D-LC, method development, and a new Online LC solution for process monitoring and process analytical technology (PAT).

The Bio LC portfolio launches at the first InfinityLab LC Virtual Conference from June 22-23, 2021. For more information visit the event registration page.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free